As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Dupilumab as add-on maintenance therapy in patients with chronic rhinosinusitis with nasal polyposis.
This review discusses inflammation and management, pharmacological properties, mechanism of action and major studies featuring Dupilumab. It also provides commentary and recommendations from Dr Connie Katelaris, Head of Unit, Immunology & Allergy, Campbelltown Hospital, NSW.
Please login below to download this issue (PDF)